The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials: A Systematic Review and Meta-analysis
R Iskander, H Moyer, D Fergusson… - Annals of Internal …, 2024 - acpjournals.org
Background: Many patients participate in cancer trials to access new therapies. The extent to
which new treatments produce clinical benefit for trial participants is unclear. Purpose: To …
which new treatments produce clinical benefit for trial participants is unclear. Purpose: To …
Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews
M Mainou, KI Bougioukas, K Malandris, A Liakos… - Annals of …, 2024 - Springer
The present study is an overview of systematic reviews focusing on adverse events of
antimyeloma treatments. It provides a systematic description of adverse events as they are …
antimyeloma treatments. It provides a systematic description of adverse events as they are …
[HTML][HTML] The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
In October 2021, melphalan flufenamide (melflufen) was withdrawn from the US market for
the treatment of multiple myeloma. The decision occurred based on results from a phase 3 …
the treatment of multiple myeloma. The decision occurred based on results from a phase 3 …
Use of suboptimal control arms in randomized clinical trials of investigational cancer drugs in China, 2016–2021: An observational study
Y Zhang, D Chen, S Cheng, Z Liang, L Yang, Q Li… - PLoS …, 2023 - journals.plos.org
Background The use of suboptimal controls in randomized trials of new cancer drugs can
produce potentially unreliable clinical efficacy results over the current standard of care and …
produce potentially unreliable clinical efficacy results over the current standard of care and …
[HTML][HTML] Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity
M Sengar, WM Hopman, GR Mohyuddin… - …, 2023 - ncbi.nlm.nih.gov
Background Design, results, and interpretation of oncology randomised controlled trials
(RCTs) have changed substantially over the past decade. In this study, we describe all RCTs …
(RCTs) have changed substantially over the past decade. In this study, we describe all RCTs …
Control Groups in RCTs Supporting Approval of Drugs for Systemic Rheumatic Diseases, 2012-2022
Y Liu, Y Xie, Y Qin, Q Xie, X Chen - JAMA Network Open, 2023 - jamanetwork.com
Importance Randomized clinical trials (RCTs) testing innovative drugs must strive to use
optimal control groups to reflect the best available treatments. A comprehensive evaluation …
optimal control groups to reflect the best available treatments. A comprehensive evaluation …
Control participants of randomised trials: an often forgotten, vulnerable population
GR Mohyuddin, N Mehra, B Ryll… - The Lancet Haematology, 2022 - thelancet.com
A lot of attention is rightfully given to racial and socioeconomic disparities in cancer care. 1 It
is certain that disadvantaged groups have less access to lifeextending oncology care, with …
is certain that disadvantaged groups have less access to lifeextending oncology care, with …
Post-protocol therapy and informative censoring in the CANDOR study
We read with great interest and wish to congratulate Saad Z Usmani and colleagues on the
CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) with …
CANDOR study comparing carfilzomib, dexamethasone, and daratumumab (KdD) with …
Utilising Health Technology Assessment to Develop Managed Access Protocols to Facilitate Drug Reimbursement in Ireland
C Gorry, M Daly, R Barrett, K Finnigan, A Smith… - … health economics and …, 2024 - Springer
Abstract The Health Service Executive, responsible for operating the Irish health service, has
introduced health technology management (HTM) initiatives to manage expenditure on …
introduced health technology management (HTM) initiatives to manage expenditure on …
Multiple myeloma: challenges with deciding the optimal sequencing strategy
The therapeutic landscape for multiple myeloma (MM) has witnessed great advances over
the past two decades, with more than 20 FDA-approved drugs currently available. The latest …
the past two decades, with more than 20 FDA-approved drugs currently available. The latest …